Dosing strategies for anticancer drugs: the good, the bad and body-surface area (Q33184074)

23 July 2017

1 reference

title

Dosing strategies for anticancer drugs: the good, the bad and body-surface area (English)

1 reference

23 July 2017

Felici A

1 reference

23 July 2017

Verweij J

series ordinal

1 reference

23 July 2017

Sparreboom A

series ordinal

1 reference

23 July 2017

publication date

1 September 2002

1 reference

European Journal of Cancer

23 July 2017

published in

1 reference

23 July 2017

1 reference

23 July 2017

1 reference

23 July 2017

page(s)

1677-1684

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900151-X

23 July 2017

1 reference

7 January 2021

Human surface area: Comparison of the du bois formula with direct photometric measurement

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900151-X

7 January 2021

Lean body mass as a predictor of drug dosage. Implications for drug therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900151-X

7 January 2021

Body size and metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900151-X

7 January 2021

Poor correlation between body surface area and glomerular filtration rate

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900151-X

7 January 2021

Is dose normalization to weight or body surface area useful in adults?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900151-X

7 January 2021

Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900151-X

7 January 2021

Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900151-X

7 January 2021

Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900151-X

7 January 2021

What is the effect of adjusting epirubicin doses for body surface area?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900151-X

7 January 2021

Population pharmacokinetics of doxorubicin, etoposide and ifosfamide in small cell lung cancer patients: results of a multicentre study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900151-X

7 January 2021

Bioequivalence of two methotrexate formulations in psoriatic and cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900151-X

7 January 2021

Relative importance of dose, body surface area, sex, and age for 5-fluorouracil clearance

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900151-X

7 January 2021

Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900151-X

7 January 2021

Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900151-X

7 January 2021

A population pharmacokinetic model for docetaxel (Taxotere): model building and validation

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900151-X

7 January 2021

Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900151-X

7 January 2021

Phase I and II clinical trials of trastuzumab

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900151-X

7 January 2021

Phase I study of ZD9331 on short daily intravenous bolus infusion for 5 days every 3 weeks with fixed dosing recommendations

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900151-X

7 January 2021

Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900151-X

7 January 2021

Long-term pharmacokinetics of doxorubicin HCl stealth liposomes in patients after polychemotherapy with vinorelbine, cyclophosphamide and prednisone (CCVP).

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900151-X

7 January 2021

Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900151-X

7 January 2021

Carboplatin dosing formulae: gender bias and the use of creatinine-based methodologies

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900151-X

7 January 2021

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900151-X

7 January 2021

Overview of recent topics in clinical pharmacology of anticancer agents

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900151-X

7 January 2021

Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900151-X

7 January 2021

Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900151-X

7 January 2021

Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900151-X

7 January 2021

Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900151-X

7 January 2021

Can dihydropyrimidine dehydrogenase impact 5-fluorouracil-based treatment?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900151-X

7 January 2021

Use of Plasma Pharmacokinetics to Predict and Prevent Methotrexate Toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900151-X

7 January 2021

Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900151-X

7 January 2021

5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900151-X

7 January 2021

Can pharmacokinetic monitoring improve clinical use of fluorouracil?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900151-X

7 January 2021

Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900151-X

7 January 2021

Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900151-X

7 January 2021

Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900151-X

7 January 2021

Population pharmacokinetics of total and unbound etoposide

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900151-X

7 January 2021

Population pharmacokinetics of temozolomide in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900151-X

7 January 2021

10.1016/S0959-8049(02)00151-X

Identifiers

DOI

1 reference

23 July 2017

1 reference